EGFR and non-small cell lung carcinoma: Since that time, several clinical trials have proved that EGFR-mutant advanced NSCLC patients with first-generation (gefitinib and erlotinib) and second-generation (afatinib) EGFR-TKI treatment experienced longer progression-free survival (PFS) and fewer adverse effects than those patients who underwent platinum-based chemotherapy7–9.